NASDAQ:ELGX - Endologix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.0225 -0.06 (-0.85 %)
(As of 03/18/2019 03:48 PM ET)
Previous Close$7.08
Today's Range$6.9273 - $7.19
52-Week Range$5.20 - $67.20
Volume129,990 shs
Average Volume119,655 shs
Market Capitalization$72.65 million
P/E Ratio-0.98
Dividend YieldN/A
Beta0.54
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions which allows physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Ovation, Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$156.47 million
Book Value$8.99 per share

Profitability

Net Income$-79,710,000.00

Miscellaneous

EmployeesN/A
Market Cap$72.65 million
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable

Endologix (NASDAQ:ELGX) Frequently Asked Questions

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

When did Endologix's stock split? How did Endologix's stock split work?

Endologix shares reverse split before market open on Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) announced its quarterly earnings results on Thursday, August, 9th. The medical instruments supplier reported ($1.80) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($1.80). The medical instruments supplier had revenue of $44.70 million for the quarter, compared to analyst estimates of $44.43 million. Endologix had a negative net margin of 50.94% and a negative return on equity of 132.78%. Endologix's revenue for the quarter was down 8.0% compared to the same quarter last year. During the same period last year, the business posted ($1.00) EPS. View Endologix's Earnings History.

When is Endologix's next earnings date?

Endologix is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Endologix.

What guidance has Endologix issued on next quarter's earnings?

Endologix issued an update on its first quarter 2019 earnings guidance on Monday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $35-35 million, compared to the consensus revenue estimate of $32.67 million.Endologix also updated its FY 2019 guidance to EPS.

What price target have analysts set for ELGX?

5 analysts have issued 12 month price targets for Endologix's shares. Their forecasts range from $30.00 to $40.00. On average, they anticipate Endologix's share price to reach $34.00 in the next year. This suggests a possible upside of 384.2% from the stock's current price. View Analyst Price Targets for Endologix.

What is the consensus analysts' recommendation for Endologix?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endologix.

What are Wall Street analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:
  • 1. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (3/11/2019)
  • 2. BTIG Research analysts commented, ": We reiterate our Overweight rating and are lowering our 12-month price target to $85/share from $86/share on AERI. Aerie Pharmaceuticals reported earnings and hosted a conference call to discuss financial and corporate updates for 4Q18/2018. The quarter produced strong Rhopressa sales of $14.5 million. Our focus in 2019 will be on a potential Rocklatan approval, company guidance for revenue projections, and the international expansion of Aerie’s glaucoma drugs to further penetrate the market potential." (2/26/2019)

Has Endologix been receiving favorable news coverage?

Media coverage about ELGX stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Endologix earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave news headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future.

Are investors shorting Endologix?

Endologix saw a increase in short interest in February. As of February 28th, there was short interest totalling 4,800,376 shares, an increase of 39.4% from the February 15th total of 3,444,065 shares. Based on an average daily trading volume, of 738,268 shares, the short-interest ratio is presently 6.5 days. Approximately 48.6% of the shares of the stock are sold short. View Endologix's Current Options Chain.

Who are some of Endologix's key competitors?

What other stocks do shareholders of Endologix own?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:
  • Mr. John Onopchenko, CEO & Director (Age 60)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)
  • Mr. Jeffrey S. Brown, Chief Operations Officer
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 49)

Who are Endologix's major shareholders?

Endologix's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.00%), Stephens Inc. AR (2.32%), D. E. Shaw & Co. Inc. (1.88%), Mackenzie Financial Corp (1.77%), Northern Trust Corp (1.18%) and Geode Capital Management LLC (1.02%). Company insiders that own Endologix stock include Christopher G Chavez, Dan Lemaitre, Guido J Neels, Robert D Mitchell and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.

Which major investors are selling Endologix stock?

ELGX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Candriam Luxembourg S.C.A. and Bank of New York Mellon Corp. View Insider Buying and Selling for Endologix.

Which major investors are buying Endologix stock?

ELGX stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, BlackRock Inc., Bank of America Corp DE, Stephens Inc. AR, D. E. Shaw & Co. Inc., Two Sigma Investments LP, SG Americas Securities LLC and Geode Capital Management LLC. Company insiders that have bought Endologix stock in the last two years include Dan Lemaitre, Guido J Neels, Robert D Mitchell and Vaseem Mahboob. View Insider Buying and Selling for Endologix.

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $7.0225.

How big of a company is Endologix?

Endologix has a market capitalization of $72.65 million and generates $156.47 million in revenue each year. The medical instruments supplier earns $-79,710,000.00 in net income (profit) each year or ($7.20) on an earnings per share basis.

What is Endologix's official website?

The official website for Endologix is http://www.endologix.com.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]


MarketBeat Community Rating for Endologix (NASDAQ ELGX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  393 (Vote Outperform)
Underperform Votes:  386 (Vote Underperform)
Total Votes:  779
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe ELGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/18/2019 by MarketBeat.com Staff

Featured Article: What is a Swap?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel